Comparative Pharmacology
Head-to-head clinical analysis: DSUVIA versus DURAGESIC 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DSUVIA versus DURAGESIC 25.
DSUVIA vs DURAGESIC-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, high-affinity agonist at the mu-opioid receptor, resulting in analgesia via activation of G-protein coupled inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels in the central nervous system.
Fentanyl is a mu-opioid receptor agonist that produces analgesia and sedation by mimicking endogenous opioids in the central nervous system.
30 mcg sublingual tablet as a single dose; may repeat once after 1 hour if needed. Maximum 2 doses per 24 hours.
Apply 25 mcg/hour transdermally every 72 hours; initial dose in opioid-naive patients: 25 mcg/hour is not recommended; use lower strength or immediate-release opioid first.
None Documented
None Documented
Terminal elimination half-life is approximately 23.4 hours (range 17–30 h), supporting once-daily dosing. Due to rapid redistribution, clinical effects may wane before elimination is complete.
Terminal elimination half-life 22-25 hours (range 13-31 h) after 72-h transdermal application; prolonged in elderly, hepatic or renal impairment
Primarily renal elimination of metabolites; unchanged drug accounts for <1% of the dose. Fecal excretion is minimal. Total recovery: ~70% in urine, ~20% in feces.
Renal (75% as metabolites, <10% unchanged); fecal (9%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic